Development of Merkel Cell Carcinoma and Squamous Cell Carcinoma During Treatment With Pembrolizumab for Metastatic Mucosal Melanoma
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al. - 46(2020), 11 vom: 01. Nov., Seite 1443-1445 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hajar, Tamar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 20.01.2021 Date Revised 06.02.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/DSS.0000000000002164 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301917280 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301917280 | ||
| 003 | DE-627 | ||
| 005 | 20231225105623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/DSS.0000000000002164 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM301917280 | ||
| 035 | |a (NLM)31584527 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hajar, Tamar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Merkel Cell Carcinoma and Squamous Cell Carcinoma During Treatment With Pembrolizumab for Metastatic Mucosal Melanoma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2021 | ||
| 500 | |a Date Revised 06.02.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a Hill, Emma E |e verfasserin |4 aut | |
| 700 | 1 | |a Leitenberger, Justin J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al. |d 1995 |g 46(2020), 11 vom: 01. Nov., Seite 1443-1445 |w (DE-627)NLM074733354 |x 1524-4725 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2020 |g number:11 |g day:01 |g month:11 |g pages:1443-1445 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/DSS.0000000000002164 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2020 |e 11 |b 01 |c 11 |h 1443-1445 | ||